Can Exercise-Powered immune cells stop leukemia from coming back?
NCT ID NCT07254793
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a new approach using donor immune cells that have been mobilized through exercise to prevent or treat leukemia relapse after a stem cell transplant. The study will enroll 94 people with various blood cancers. Some will receive the exercise-mobilized cells to prevent relapse, while others will get them to treat minimal residual disease or active relapse. The goal is to see if these cells are safe and more effective than standard donor lymphocyte infusions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
exercise-mobilized NK-enriched donor lymphocyte infusions (DLI-X)
What this could lead to
If successful, this approach could offer a safer and more effective way to prevent or treat leukemia relapse after stem cell transplant, potentially improving survival and quality of life.
What could go wrong
This is a very early first-in-human trial with a small number of participants. The treatment may not work as hoped, and there are risks of graft-versus-host disease or other serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
The University of Arizona Cancer Center
Tucson, Arizona, 85719, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Email: •••••@•••••